The lack of a viable commercial route for bringing innovative antibacterial treatments to market leaves France-based Antabio SAS little option other than to seek a partner or acquirer after early-stage clinical data are generated from its lead program, its CEO Marc Lemonnier told Scrip.
Antabio CEO Says M&A Is His ‘Exit Strategy’
‘Broken’ AMR Model Leaves Antibiotics Maker No Other Choice
Antibiotics specialist Antabio aims to get enough funding to advance its pipeline far enough to become a takeover target.
More from Business
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
More from Scrip
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.